Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.55 |
| ▸ | STK17B | O94768 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586619 | 0.94 | STK17B (0.50) | STK17ASTK17BSYKMAPTCTSK | |
| SCHEMBL11935539 | 0.93 | STK17B (0.49) | STK17ASTK17BSYKMAPTCTSK | |
| SCHEMBL4409856 | 0.88 | STK17B (0.43) | STK17ASTK17BMAPTCTSKGAA | |
| SCHEMBL2064181 | 0.88 | MAPT (0.54) | MAPTCTSKGAAALDH1A1EPHX1 | |
| SCHEMBL11748511 | 0.83 | MAPT (0.52) | STK17AMAPTGAAALDH1A1PRSS1 | |
| SCHEMBL854855 | 0.82 | EPHX1 (0.51) | STK17ASTK17BMAPTGAAALDH1A1 | |
| SCHEMBL12461775 | 0.82 | PRSS1 (0.40) | STK17ASTK17BMAPTGAAALDH1A1 | |
| SCHEMBL11113503 | 0.81 | ALDH1A1 (0.47) | STK17ASTK17BMAPTALDH1A1EPHX1 | |
| SCHEMBL11117632 | 0.81 | STK17B (0.45) | STK17ASTK17BMAPTGAAALDH1A1 | |
| SCHEMBL20883650 | 0.80 | MAPT (0.46) | STK17ASTK17BMAPTCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013170072-A2 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NEUROP, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | STK17A 448/4885STK17B 421/4885SYK 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.